journal article·2015-02

Comparison of human olfactory and skeletal MSCs using osteogenic nanotopography to demonstrate bone-specific bioactivity of the surfaces

Steven A. Johnstone, Martha Liley, Matthew J. Dalby, Susan C. Barnett

Acta Biomaterialia· Volume 13
Publisher page

Abstract

Recently we identified a novel population of mesenchymal stem cells (MSCs) from human olfactory mucosa (OM-MSCs), a tissue which promotes neurogenesis throughout life, and demonstrated that they promoted CNS myelination to a greater extent than bone marrow-derived (BM)-MSCs. Previous data demonstrated that nanotopographies with a degree of disorder induce BM-MSC osteogenic differentiation. Thus, using biomaterials as non-chemical tools, we investigated if MSCs from a completely different cellular niche could be induced to differentiate similarly to nanoscale cues alone. Both MSCs differentiated into bone when cultured on nanotopographically embossed polycaprolactone (PCL) with a disordered pattern and heights but not on a "smooth" non-embossed PCL control substrate, but OM-MSC changes were at lower expression levels. Both MSCs showed similar increases in differentiation markers at the protein and mRNA level when plated on the two patterned surfaces. Thus, topographical cues from substrates with disordered patterns can up-regulate several MSC resident genes in both BM-MSCs and OM-MSCs. Moreover, antibody purified BM-MSCs had similar properties to non-purified BM-MSCs. These data suggest that MSCs from a neural cellular niche express similar bone-induced cues to BM-MSCs, suggesting that MSCs that inherently support nervous tissue can differentiate along the bone lineage in a similar manner to MSCs from a skeletal environment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Mesenchymal stem cell research · Neurogenesis and neuroplasticity mechanisms · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (61)

Show source-provided references
1. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors10.1634/stemcells.2007-0280 ↗
2. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis10.1179/016164106X116791 ↗
3. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells10.1038/icb.2012.64 ↗
4. Immunomodulatory effects of stem cells
5. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide10.1016/j.stem.2007.11.014 ↗
6. Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli10.1016/j.cyto.2010.01.004 ↗
7. Mesenchymal stem cells as trophic mediators10.1002/jcb.20886 ↗
8. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model10.1242/jcs.113.7.1161 ↗
9. Multilineage potential of adult human mesenchymal stem cells10.1126/science.284.5411.143 ↗
10. Mesenchymal stem cells migration homing and tracking10.1155/2013/130763 ↗
11. High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA10.1186/scrt153 ↗
12. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms10.1007/s11684-011-0114-1 ↗
13. Mesenchymal stem cells for ischemic stroke: changes in effects after ex vivo culturing10.3727/096368908786991551 ↗
14. Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke10.1161/STROKEAHA.111.000326 ↗
15. Honmou · Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke brain · 2011 · 134 · 1790
16. Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities
17. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms10.1007/s12015-012-9375-6 ↗
18. Mesenchymal stem cells for cardiac regenerative therapy10.1007/978-3-540-68976-8_9 ↗
19. Mesenchymal stem cells for cardiac cell therapy10.1089/hum.2010.211 ↗
20. Mesenchymal stem cell therapy for cardiac repair10.1007/978-1-60761-705-1_5 ↗
21. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans10.1227/NEU.0b013e31824387f9 ↗
22. Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells10.1097/CCM.0b013e3181f17c0e ↗
23. Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury. Systematic review with meta-analyses of rat models10.1016/j.nbd.2013.10.014 ↗
24. Mesenchymal stem cells as treatment for MS – progress to date10.1177/1352458512464686 ↗
25. Nanotopographical control of human osteoprogenitor differentiation10.2174/157488807780599220 ↗
26. Optimizing the osteogenicity of nanotopography using block co-polymer phase separation fabrication techniques10.1002/jor.22076 ↗
27. The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder10.1038/nmat2013 ↗
28. Harnessing nanotopography and integrin–matrix interactions to influence stem cell fate10.1038/nmat3980 ↗
29. Investigation of the limits of nanoscale filopodial interactions10.1177/2041731414536177 ↗
30. Surface structure of thin film blends of polystyrene and poly (n-butylmethacrylate)10.1007/s003960000358 ↗
31. The effect of molecular weight and the topography of thin films of blends of poly-(4-bromostyrene) and polystyrene10.1007/s003960000359 ↗
32. Fabrication of nanostructures with long-range order using block copolymer lithography10.1063/1.1519356 ↗
33. Block copolymer micelles as switchable templates for nanofabrication10.1021/la052299a ↗
34. Tuning the dimensions and periodicities of nanostructures starting from the same polystyrene-block-poly(2-vinylpyridine) diblock copolymer10.1002/adfm.200500524 ↗
35. Identification of nonepithelial multipotent cells in the embryonic olfactory mucosa10.1002/stem.130 ↗
36. Multipotent stem cells from adult olfactory mucosa10.1002/dvdy.20360 ↗
37. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties10.1089/scd.2009.0267 ↗
38. Neural regeneration and the peripheral olfactory system10.1002/ar.10047 ↗
39. Glial influences on axonal growth in the primary olfactory system10.1002/glia.440030602 ↗
40. Olfactory neurogenesis: genetic or environmental controls?10.1016/0166-2236(90)90017-5 ↗
41. Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelination in vitro10.1002/glia.22440 ↗
42. MSCs guide neurite directional extension and promote oligodendrogenesis in NSCs10.1016/j.bbrc.2009.04.147 ↗
43. Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures10.1159/000233256 ↗
44. Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation10.1371/journal.pone.0071814 ↗
45. A complex tissue for a complex injury?10.1002/glia.20917 ↗
46. Osteoprogenitor response to semi-ordered and random nanotopographies10.1016/j.biomaterials.2006.01.010 ↗
47. Stem cell therapy to cure type 1 diabetes: from hype to hope10.5966/sctm.2012-0116 ↗
48. Mesenchymal stem cells: promising for myocardial regeneration?10.2174/1574888X11308040002 ↗
49. Stem cell applications in regenerative medicine for neurological disorders10.3727/096368912X655145 ↗
50. The past, present and future of stem cell clinical trials for ALS10.1016/j.expneurol.2014.02.021 ↗
51. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study10.1016/S1474-4422(11)70305-2 ↗
52. Concise review: the surface markers and identity of human mesenchymal stem cells10.1002/stem.1681 ↗
53. Clonal analysis of nestin(−) vimentin(+) multipotent fibroblasts isolated from human dermis10.1242/jcs.03478 ↗
54. Expression of neural markers by undifferentiated mesenchymal-like stem cells from different sources10.1155/2014/987678 ↗
55. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker10.1634/theoncologist.2013-0075 ↗
56. Class III β-tubulin, a novel biomarker in the human melanocyte lineage10.1016/j.diff.2013.05.003 ↗
57. Highexpression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer10.1016/j.clbc.2012.11.003 ↗
58. Positivity to glial fibrillary acidic protein in bone, cartilage, and chordoma10.1002/jso.2930410109 ↗
59. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche10.1038/nature09262 ↗
60. CNS stem cells express a new class of intermediate filament protein10.1016/0092-8674(90)90662-X ↗
61. PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion10.1084/jem.20122252 ↗